Trice Medical, a Malvern, PA-based imaging technology company, raised a Series D funding led by Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing.
The amount of the deal was not disclosed.
In conjunction with leading the funding, Bioventus will receive exclusive sales and distribution rights to Trice’s products outside of the US. Bioventus and Trice have also agreed to enter into a co-development arrangement to explore the integration of technologies with certain Bioventus offerings in order to accelerate adoption of both companies’ products.
Led by Mark Foster, CEO and President, Trice Medical provides imaging technology that enables orthopedic procedures to be done on its portable, tablet-based system. The company developed a platform that combines a disposable needle camera (mi-eye™) with a high-quality ultrasound transducer (mi-ultra™). Since 2019, Trice has acquired Seg-WAY™ Orthopedics and Tenex Health, a leader in minimally invasive ultrasonic technology for the treatment of chronic pain in soft and hard tissue.
FinSMEs
27/08/2021